ALK→Fusion→Crizotinib→FDA US 2011-08-26→7 active / 15 trials
Curatedlevel Asensitivity· support 3civic·Observedcohort frequency not yet available for ALK in this cancer·Regulatoryapproved for Anaplastic Large Cell Lymphoma (4 approval records)·context: Anaplastic Large Cell Lymphoma
EZH2→A682G→Tazemetostat→FDA US 2020-01-23→10 active / 23 trials
Curatedlevel Asensitivity· support 2civic·ObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)·Regulatoryapproved for Follicular Lymphoma (2 approval records)·context: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma
EZH2→A692V→Tazemetostat→FDA US 2020-01-23→10 active / 23 trials
Curatedlevel Asensitivity· support 2civic·ObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)·Regulatoryapproved for Follicular Lymphoma (2 approval records)·context: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma
EZH2→Activating Mutation→Tazemetostat→FDA US 2020-01-23→10 active / 23 trials
Curatedlevel Asensitivity· support 2civic·ObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)·Regulatoryapproved for Follicular Lymphoma (2 approval records)·context: Follicular Lymphoma
EZH2→Y646C→Tazemetostat→FDA US 2020-01-23→10 active / 23 trials
Curatedlevel Asensitivity· support 2civic·ObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)·Regulatoryapproved for Follicular Lymphoma (2 approval records)·context: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma
EZH2→Y646F→Tazemetostat→FDA US 2020-01-23→10 active / 23 trials
Curatedlevel Asensitivity· support 2civic·ObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)·Regulatoryapproved for Follicular Lymphoma (2 approval records)·context: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma
EZH2→Y646H→Tazemetostat→FDA US 2020-01-23→10 active / 23 trials
Curatedlevel Asensitivity· support 2civic·ObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)·Regulatoryapproved for Follicular Lymphoma (2 approval records)·context: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma
EZH2→Y646N→Tazemetostat→FDA US 2020-01-23→10 active / 23 trials
Curatedlevel Asensitivity· support 2civic·ObservedEZH2 altered in 6.1% (61 / 1,001 cases, largest of 3 cohorts)·Regulatoryapproved for Follicular Lymphoma (2 approval records)·context: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma
Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.